|
Eveolocumab lowers LDL cholesterol in patients with marked hypercholesterolemia. |
 |
 |
|
Amgen: The 52-week open label study, showed that monthly treatment Evolocumab reduced cholesterol levels up to 52 percent in combination with SOC in patients with high cholesterol, and also prevented major increase in adverse events. Meanwhile, 81.4 percent of patients showed adverse events including nasopharyngitis, upper respiratory tract infections, influenza, arthralgia, and back pain. Other minor reported events include muscle-problems, elevated liver function, elevated creatine kinase.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
